Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/20109Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Psilas, K. | en |
| dc.contributor.author | Petroutsos, G. | en |
| dc.contributor.author | Aspiotis, M. | en |
| dc.date.accessioned | 2015-11-24T19:04:53Z | - |
| dc.date.available | 2015-11-24T19:04:53Z | - |
| dc.identifier.issn | 0181-5512 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/20109 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adolescent | en |
| dc.subject | Adult | en |
| dc.subject | Child | en |
| dc.subject | Chorioretinitis/*drug therapy | en |
| dc.subject | Drug Therapy, Combination | en |
| dc.subject | Female | en |
| dc.subject | Follow-Up Studies | en |
| dc.subject | Humans | en |
| dc.subject | Male | en |
| dc.subject | Prednisone/*therapeutic use | en |
| dc.subject | Pyrimethamine/*therapeutic use | en |
| dc.subject | Recurrence | en |
| dc.subject | Sulfonamides/*therapeutic use | en |
| dc.subject | Toxoplasmosis, Ocular/*drug therapy | en |
| dc.title | Treatment of toxoplasmosis. The treatment of toxoplasmic chorioretinitis | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/2081846 | - |
| heal.language | fr | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1990 | - |
| heal.abstract | Toxoplasmosis is the commonest cause of inflammatory disease of the posterior segment of the eye. We treated 23 patients with acute toxoplasma chorioretinitis with sulfonamides, pyrimethamine and corticosteroids for a period of 4 weeks. All patients with acute disease had characteristic foci and a positive titer on the Sabin-Feldman dye test. In all patients, we observed clinical improvement within 2 weeks, but one patient with a lesion larger than 2 disc diameters improved after the third week. During the follow-up period ranging from 6 months to 6 years (mean 2.5 years), there have been four recurrences (17%). No serious side effects of treatment were observed in our patients. | en |
| heal.journalName | J Fr Ophtalmol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
